Amendment to Schedule 13D for NovaBay Pharmaceuticals, Inc.

This filing is an amendment to the Schedule 13D for NovaBay Pharmaceuticals, Inc., filed by David E. Lazar. The amendment updates the ownership details and transactions involving the company's Series D and Series E Preferred Stock. Specifically, it details the sale of 441,325 shares of Series D Preferred Stock and the rights to purchase 268,750 shares of Series E Preferred Stock to R01 Fund LP and Framework Ventures IV L.P. for a total of $12,000,000. The amendment also includes the resignation of David E. Lazar as Chief Executive Officer and director of the company, effective upon the release of escrow funds. The filing provides a comprehensive overview of the transactions, including the terms of the Securities Purchase Agreement and the conditions for closing.